Annotation Detail
Information
- Associated Genes
- NTRK3
- Associated Variants
- NTRK3 ETV6-NTRK3
- Associated Disease
- salivary gland carcinoma
- Source Database
- CIViC Evidence
- Description
- Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after 18 weeks. The patient was subsequently treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1870
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3985
- Variant URL
- https://civic.genome.wustl.edu/links/variants/801
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Salivary Gland Carcinoma
- Evidence Direction
- Does Not Support
- Drug
- Crizotinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26884591
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Sensitivity | false |